CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (<i>Enterococcus</i>...
Main Authors: | Manuel González de Aledo, Mónica González-Bardanca, Lucía Blasco, Olga Pacios, Inés Bleriot, Laura Fernández-García, Melisa Fernández-Quejo, María López, Germán Bou, María Tomás |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/7/756 |
Similar Items
-
Application of CRISPR-Cas system in the diagnosis and therapy of ESKAPE infections
by: Yizheng Qian, et al.
Published: (2023-08-01) -
Comparison of CRISPR–Cas Immune Systems in Healthcare-Related Pathogens
by: Kate Mortensen, et al.
Published: (2021-10-01) -
Reverse Transcription-Loop-Mediated Isothermal Amplification-CRISPR-Cas13a Technology as a Promising Diagnostic Tool for SARS-CoV-2
by: Concha Ortiz-Cartagena, et al.
Published: (2022-10-01) -
Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens
by: Tanzeel Zohra, et al.
Published: (2021-04-01) -
Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
by: Fei Zhang, et al.
Published: (2019-06-01)